Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis.
Chefdeville A, Treilleux I, Mayeur ME, Couillault C, Picard G, Bost C, Mokhtari K, Vasiljevic A, Meyronet D, Rogemond V, Psimaras D, Dubois B, Honnorat J, Desestret V. Chefdeville A, et al. Among authors: couillault c. Acta Neuropathol Commun. 2019 Mar 11;7(1):38. doi: 10.1186/s40478-019-0693-7. Acta Neuropathol Commun. 2019. PMID: 30857565 Free PMC article.
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V. Small M, et al. Among authors: couillault c. Acta Neuropathol. 2018 Apr;135(4):569-579. doi: 10.1007/s00401-017-1802-y. Epub 2018 Jan 3. Acta Neuropathol. 2018. PMID: 29299667
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer.
Hubert M, Gobbini E, Couillault C, Manh TV, Doffin AC, Berthet J, Rodriguez C, Ollion V, Kielbassa J, Sajous C, Treilleux I, Tredan O, Dubois B, Dalod M, Bendriss-Vermare N, Caux C, Valladeau-Guilemond J. Hubert M, et al. Among authors: couillault c. Sci Immunol. 2020 Apr 17;5(46):eaav3942. doi: 10.1126/sciimmunol.aav3942. Epub 2020 Apr 17. Sci Immunol. 2020. PMID: 32303573
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.
Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. Hsieh RC, et al. Among authors: couillault ca. Sci Immunol. 2022 Jun 10;7(72):eabl9330. doi: 10.1126/sciimmunol.abl9330. Epub 2022 Jun 10. Sci Immunol. 2022. PMID: 35687697 Free PMC article.
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. Hegde A, et al. Among authors: couillault ca. Clin Cancer Res. 2021 Jun 1;27(11):3050-3060. doi: 10.1158/1078-0432.CCR-20-4118. Epub 2021 Mar 26. Clin Cancer Res. 2021. PMID: 33771853 Free PMC article. Clinical Trial.
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Nardo M, Gouda MA, Reilley MJ, Biter AB, Lim J, Bean SA, Nguyen LM, Bhosale PR, Ager CR, Couillault CA, Piha-Paul SA, Fu S, Tsimberidou AM, Yap TA, Naing A, Rodon J, Subbiah V, Karp DD, Curran MA, Hong DS. Nardo M, et al. Among authors: couillault ca. J Immunother Precis Oncol. 2025 Feb 7;8(2):89-98. doi: 10.36401/JIPO-24-17. eCollection 2025 May. J Immunother Precis Oncol. 2025. PMID: 39959251 Free PMC article.
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
Tang C, Hartley GP, Couillault C, Yuan Y, Lin H, Nicholas C, Srinivasamani A, Dai J, Dumbrava EEI, Fu S, Karp DD, Naing A, Piha-Paul SA, Rodon Ahnert J, Pant S, Subbiah V, Yap TA, Tsimberidou AM, Guerrero P, Dhebat S, Proia T, Curran MA, Hong DS. Tang C, et al. Among authors: couillault c. BMJ Oncol. 2024 Jul 30;3(1):e000133. doi: 10.1136/bmjonc-2023-000133. eCollection 2024. BMJ Oncol. 2024. PMID: 39886125 Free PMC article.
39 results